Haleon PLC
11 August 2026
Haleon plc: Cash tender offer for outstanding 2027 3.375% Fixed Rate Notes
Note: This announcement is being released in accordance with DTR 6.3.10 R. In the United Kingdom, the Tender Offer is only available to relevant persons, as described under "Non-U.S. Distribution Restrictions - United Kingdom" in the full announcement linked below.
11 August 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces
that its wholly owned subsidiary, Haleon US Capital LLC (the "Offeror") is offering to buy back any and all of its outstanding $1,999,350,000 3.375% Fixed Rate Senior Notes due March 2027. Bondholders will receive a price equal to the Total Consideration based on the Reference Yield and the Fixed Spread plus Accrued Interest (each as defined in the full announcement) (the "Tender Offer").
This Tender Offer is in line with Haleon's previously stated capital allocation priorities. Together, with the planned issue of new bonds, it is expected to help the Company to proactively manage and optimise its debt portfolio. The full announcement is available at http://www.rns-pdf.londonstockexchange.com/rns/2411Q_1-2026-8-11.pdf.
The full announcement will also be available on the Haleon website www.haleon.com/investors, and has been submitted in full unedited text to the Financial Conduct Authority's National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries
|
Investors |
Media
|
||
|
Jo Russell |
+44 7787 392441 |
Zoë Bird |
+44 7736 746167 |
|
Rakesh Patel |
+44 7552 484646 |
Gemma Thomas |
+44 7985 175048 |
|
Email: investor-relations@haleon.com |
Email: corporate.media@haleon.com |
||
|
Treasury |
|||
|
Mike Rowe |
+44 7775 012365 |
||
|
Ben Checkland |
+44 7823 370368 |
||
|
Email: cf-treasury@haleon.com |
|||
About Haleon
Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.
For more information, please visitwww.haleon.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.